Category: Semaglutide
-
The Peptide Moat: Who Actually Controls the Post-Patent GLP-1 Supply Chain?
1. The Molecule: Why You Can’t Just “Print” a GLP-1 To understand why the GLP-1 boom is generating such massive B2B wealth, you first have to understand why generic pharmaceutical companies can’t just churn out semaglutide the way they do paracetamol or blood pressure pills. The barrier to entry isn’t just the expired patent—it’s the…
Therapeutic Bridge 